Pamela Bjorkman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3485773/publications.pdf

Version: 2024-02-01

243 papers	44,690 citations	3334 91 h-index	2332 199 g-index
289 all docs	289 docs citations	289 times ranked	34693 citing authors

#	Article	IF	Citations
1	Severe Acute Respiratory Syndrome Coronavirus 2 Viremia Is Associated With Coronavirus Disease 2019 Severity and Predicts Clinical Outcomes. Clinical Infectious Diseases, 2022, 74, 1525-1533.	5.8	96
2	Innovative vaccine approachesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1511, 59-86.	3.8	5
3	B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. PLoS Pathogens, 2022, 18, e1010179.	4.7	6
4	Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell Host and Microbe, 2022, 30, 69-82.e10.	11.0	42
5	Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display. Cell Reports, 2022, 38, 110348.	6.4	14
6	Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity, 2022, 55, 341-354.e7.	14.3	21
7	Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer. Nature Communications, 2022, 13, 732.	12.8	19
8	A gut-derived metabolite alters brain activity and anxiety behaviour in mice. Nature, 2022, 602, 647-653.	27.8	179
9	Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. Nature Communications, 2022, 13, .	12.8	4
10	Comparing methods for immobilizing HIV-1 SOSIPs in ELISAs that evaluate antibody binding. Scientific Reports, 2022, 12, .	3.3	3
11	Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science, 2022, 377, .	12.6	120
12	Lower Respiratory Tract Myeloid Cells Harbor SARS-Cov-2 and Display an Inflammatory Phenotype. Chest, 2021, 159, 963-966.	0.8	10
13	Evolution of antibody immunity to SARS-CoV-2. Nature, 2021, 591, 639-644.	27.8	1,355
14	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science, 2021, 371, 735-741.	12.6	305
15	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	27.8	1,232
16	Cryo-EM structures of HIV-1 trimer bound to CD4-mimetics BNM-III-170 and M48U1 adopt a CD4-bound open conformation. Nature Communications, 2021, 12, 1950.	12.8	22
17	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature, 2021, 593, 424-428.	27.8	108
18	Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers. PLoS ONE, 2021, 16, e0247963.	2.5	36

#	Article	IF	Citations
19	Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. Journal of Experimental Medicine, 2021, 218, .	8.5	25
20	Investigate the origins of COVID-19. Science, 2021, 372, 694-694.	12.6	92
21	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology, 2021, 160, 2435-2450.e34.	1.3	118
22	InÂvitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2. Molecular Therapy - Methods and Clinical Development, 2021, 21, 161-170.	4.1	4
23	The Evolution of Interdependence in a Four-Way Mealybug Symbiosis. Genome Biology and Evolution, 2021, 13, .	2.5	9
24	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell, 2021, 184, 3205-3221.e24.	28.9	73
25	In vivo imaging of retrovirus infection reveals a role for Siglec-1/CD169 in multiple routes of transmission. ELife, 2021, 10, .	6.0	7
26	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nature Communications, 2021, 12, 4196.	12.8	332
27	Neutralizing antibodies against coronaviruses. Microscopy and Microanalysis, 2021, 27, 1112-1113.	0.4	0
28	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Nature Communications, 2021, 12, 4886.	12.8	65
29	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021, 54, 1853-1868.e7.	14.3	230
30	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760.	6.4	80
31	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity, 2021, 54, 2143-2158.e15.	14.3	155
32	Nâ€Terminal Modification of Glyâ€Hisâ€Tagged Proteins with Azidogluconolactone. ChemBioChem, 2021, 22, 3199-3207.	2.6	6
33	Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. Clinical Infectious Diseases, 2021, 73, e815-e821.	5.8	113
34	How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. Viruses, 2021, 13, 2106.	3.3	7
35	Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope. Npj Vaccines, 2021, 6, 126.	6.0	2
36	Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Science Translational Medicine, 2021, 13, eabk1533.	12.4	27

#	Article	IF	Citations
37	Can we use structural knowledge to design a protective vaccine against HIVâ€1?. Hla, 2020, 95, 95-103.	0.6	5
38	Nanoparticles presenting clusters of CD4 expose a universal vulnerability of HIV-1 by mimicking target cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18719-18728.	7.1	21
39	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature, 2020, 588, 682-687.	27.8	1,346
40	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	27.8	1,742
41	De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Science, 2020, 370, 1208-1214.	12.6	172
42	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell, 2020, 182, 828-842.e16.	28.9	724
43	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell, 2020, 180, 471-489.e22.	28.9	106
44	A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7981-7989.	7.1	24
45	Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9865-9875.	7.1	7
46	An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein. ELife, 2020, 9, .	6.0	21
47	Electron tomography visualization of HIV-1 fusion with target cells using fusion inhibitors to trap the pre-hairpin intermediate. ELife, 2020, 9, .	6.0	37
48	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. ELife, 2020, 9, .	6.0	10
49	Harnessing Avidity: Quantifying the Entropic and Energetic Effects of Linker Length and Rigidity for Multivalent Binding of Antibodies to HIV-1. Cell Systems, 2019, 9, 466-474.e7.	6.2	20
50	Peptidoglycan Production by an Insect-Bacterial Mosaic. Cell, 2019, 179, 703-712.e7.	28.9	75
51	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity, 2019, 50, 1513-1529.e9.	14.3	85
52	Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature, 2019, 570, 468-473.	27.8	145
53	Endocytosis of commensal antigens by intestinal epithelial cells regulates mucosal T cell homeostasis. Science, 2019, 363, .	12.6	121
54	Asymmetric opening of HIV-1 Env bound to CD4 and a coreceptor-mimicking antibody. Nature Structural and Molecular Biology, 2019, 26, 1167-1175.	8.2	43

#	Article	IF	Citations
55	A Protective Role for the Lectin CD169/Siglec-1 against a Pathogenic Murine Retrovirus. Cell Host and Microbe, 2019, 25, 87-100.e10.	11.0	26
56	Mechanisms of virus dissemination in bone marrow of HIV-1â€“infected humanized BLT mice. ELife, 2019, 8, .	6.0	24
57	Gut microbiota utilize immunoglobulin A for mucosal colonization. Science, 2018, 360, 795-800.	12.6	447
58	Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nature Communications, 2018, 9, 1251.	12.8	85
59	HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Cell Host and Microbe, 2018, 24, 703-716.e3.	11.0	95
60	Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host and Microbe, 2018, 24, 717-730.e5.	11.0	78
61	A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates. Cell Reports, 2018, 25, 1385-1394.e7.	6.4	61
62	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 2018, 561, 479-484.	27.8	392
63	Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. Cell Host and Microbe, 2018, 24, 579-592.e4.	11.0	88
64	DEER Spectroscopy Measurements Reveal Multiple Conformations of HIV-1 SOSIP Envelopes that Show Similarities with Envelopes on Native Virions. Immunity, 2018, 49, 235-246.e4.	14.3	68
65	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Science Translational Medicine, 2017, 9, .	12.4	128
66	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nature Medicine, 2017, 23, 185-191.	30.7	399
67	Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell, 2017, 169, 597-609.e11.	28.9	279
68	LEM2 recruits CHMP7 for ESCRT-mediated nuclear envelope closure in fission yeast and human cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2166-E2175.	7.1	149
69	X-ray and EM structures of a natively glycosylated HIV-1 envelope trimer. Acta Crystallographica Section D: Structural Biology, 2017, 73, 822-828.	2.3	13
70	Multiscale Imaging of HIV-1 Transmission in Humanized Mice. AIDS Research and Human Retroviruses, 2017, 33, S-6-S-7.	1.1	4
71	Longitudinal imaging of HIV-1 spread in humanized mice with parallel 3D immunofluorescence and electron tomography. ELife, 2017, 6, .	6.0	27
72	Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice. PLoS ONE, 2017, 12, e0183377.	2.5	10

#	Article	IF	Citations
73	Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. ELife, 2017, 6, .	6.0	52
74	The structure and dynamics of secretory component and its interactions with polymeric immunoglobulins. ELife, 2016, 5, .	6.0	86
75	Structural basis for germline antibody recognition of HIV-1 immunogens. ELife, 2016, 5, .	6.0	68
76	Comparative analysis of anti-polyglutamine Fab crystals grown on Earth and in microgravity. Acta Crystallographica Section F, Structural Biology Communications, 2016, 72, 762-771.	0.8	3
77	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science, 2016, 352, 997-1001.	12.6	263
78	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nature Structural and Molecular Biology, 2016, 23, 906-915.	8.2	188
79	Biophysical and Biochemical Characterization of Avian Secretory Component Provides Structural Insights into the Evolution of the Polymeric Ig Receptor. Journal of Immunology, 2016, 197, 1408-1414.	0.8	17
80	Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7151-E7158.	7.1	130
81	Characterization of Antibody Bipolar Bridging Mediated by the Human Cytomegalovirus Fc Receptor gp68. Journal of Virology, 2016, 90, 3262-3267.	3.4	13
82	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature, 2016, 535, 556-560.	27.8	400
83	V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 237-245.	2.1	7
84	A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. Journal of Virology, 2016, 90, 2127-2134.	3.4	69
85	Structure of an HIV-2 gp120 in Complex with CD4. Journal of Virology, 2016, 90, 2112-2118.	3.4	19
86	Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcÎ³RIIIa. Journal of Structural Biology, 2016, 194, 78-89.	2.8	44
87	Antibody engineering for increased potency, breadth and half-life. Current Opinion in HIV and AIDS, 2015, 10, 151-159.	3.8	46
88	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathogens, 2015, 11, e1005238.	4.7	43
89	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292.	28.9	305
90	Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1. Cell, 2015, 160, 433-446.	28.9	109

#	Article	IF	Citations
91	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell, 2015, 161, 1505-1515.	28.9	239
92	Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection. Science, 2015, 350, 563-567.	12.6	155
93	CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Research, 2015, 43, W213-W219.	14.5	118
94	Whole-body tissue stabilization and selective extractions via tissue-hydrogel hybrids for high-resolution intact circuit mapping and phenotyping. Nature Protocols, 2015, 10, 1860-1896.	12.0	234
95	Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. MBio, 2015, 6, .	4.1	25
96	Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. Cell, 2015, 162, 1379-1390.	28.9	132
97	Anti-PolyQ Antibodies Recognize a Short PolyQ Stretch in Both Normal and Mutant Huntingtin Exon 1. Journal of Molecular Biology, 2015, 427, 2507-2519.	4.2	31
98	Not Second Class: The First Class II MHC Crystal Structure. Journal of Immunology, 2015, 194, 3-4.	0.8	8
99	Electron Tomography of HIV-1 Infection in Gut-Associated Lymphoid Tissue. PLoS Pathogens, 2014, 10, e1003899.	4.7	45
100	The Herpes Virus Fc Receptor gE-gI Mediates Antibody Bipolar Bridging to Clear Viral Antigens from the Cell Surface. PLoS Pathogens, 2014, 10, e1003961.	4.7	35
101	Engineering Antibodies to Enhance Activity and Increase Half-life. AIDS Research and Human Retroviruses, 2014, 30, A210-A210.	1.1	2
102	Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. Journal of Experimental Medicine, 2014, 211, 2361-2372.	8.5	79
103	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. Journal of Experimental Medicine, 2014, 211, 2061-2074.	8.5	297
104	Drift of the HIV-1 Envelope Glycoprotein gp120 toward Increased Neutralization Resistance over the Course of the Epidemic: a Comprehensive Study Using the Most Potent and Broadly Neutralizing Monoclonal Antibodies. Journal of Virology, 2014, 88, 13910-13917.	3.4	42
105	Design and characterization of structured protein linkers with differing flexibilities. Protein Engineering, Design and Selection, 2014, 27, 325-330.	2.1	97
106	Structural Characterization of Anti-Inflammatory Immunoglobulin G Fc Proteins. Journal of Molecular Biology, 2014, 426, 3166-3179.	4.2	126
107	Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy. Cell, 2014, 156, 633-648.	28.9	318
108	Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike. Cell Reports, 2014, 7, 785-795.	6.4	199

#	Article	IF	Citations
109	Structural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12. Cell Reports, 2013, 5, 1443-1455.	6.4	36
110	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16538-16543.	7.1	247
111	Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6049-6054.	7.1	60
112	Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization. Cell, 2013, 153, 126-138.	28.9	478
113	Computational analysis of antiâ€“HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10598-10603.	7.1	106
114	Phenotypic properties of transmitted founder HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6626-6633.	7.1	379
115	Restricting HIV-1 pathways for escape using rationally designed antiâ€“HIV-1 antibodies. Journal of Experimental Medicine, 2013, 210, 1235-1249.	8.5	85
116	Intracellular Trafficking of an Antibody Bipolar Bridged Complex of HSVâ€1 gEâ€gI, IgG, and a Viral Antigen. FASEB Journal, 2013, 27, 767.3.	0.5	0
117	Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2083-90.	7.1	212
118	Single-Chain Fv-Based Anti-HIV Proteins: Potential and Limitations. Journal of Virology, 2012, 86, 195-202.	3.4	29
119	A mouse model for HIV-1 entry. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15859-15864.	7.1	75
120	Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3268-77.	7.1	505
121	Electron tomography of late stages of FcRn-mediated antibody transcytosis in neonatal rat small intestine. Molecular Biology of the Cell, 2012, 23, 2537-2545.	2.1	27
122	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 2012, 492, 118-122.	27.8	463
123	A Model System to Investigate Antibody Bipolar Bridging Mediated by gEâ€gI, a Herpes Virus Fc Receptor. FASEB Journal, 2012, 26, 605.8.	0.5	0
124	Crystal structure of a hemojuvelin-binding fragment of neogenin at 1.8Ã.... Journal of Structural Biology, 2011, 174, 239-244.	2.8	12
125	Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science, 2011, 333, 1633-1637.	12.6	1,046
126	Structure of FcRY, an avian immunoglobulin receptor related to mammalian mannose receptors, and its complex with IgY. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12431-12436.	7.1	36

#	Article	IF	Citations
127	Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18406-18411.	7.1	70
128	Designed oligomers of cyanovirin-N show enhanced HIV neutralization. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14079-14084.	7.1	38
129	Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design. Science, 2011, 334, 1289-1293.	12.6	345
130	An intracellular traffic jam: Fc receptor-mediated transport of immunoglobulin G. Current Opinion in Structural Biology, 2010, 20, 226-233.	5.7	37
131	Comparison of FcRnâ€•and pIgRâ€Mediated Transport in MDCK Cells by Fluorescence Confocal Microscopy. Traffic, 2010, 11, 1205-1220.	2.7	28
132	Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nature Structural and Molecular Biology, 2010, 17, 608-613.	8.2	92
133	Few and Far Between: How HIV May Be Evading Antibody Avidity. PLoS Pathogens, 2010, 6, e1000908.	4.7	226
134	Evaluation of CD4-CD4i Antibody Architectures Yields Potent, Broadly Cross-Reactive Anti-Human Immunodeficiency Virus Reagents. Journal of Virology, 2010, 84, 261-269.	3.4	34
135	Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3505-3510.	7.1	409
136	Dimeric 2G12 as a Potent Protection against HIV-1. PLoS Pathogens, 2010, 6, e1001225.	4.7	35
137	A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity. Aids, 2010, 24, 1633-1640.	2.2	30
138	Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7385-7390.	7.1	146
139	Design and Expression of a Dimeric Form of Human Immunodeficiency Virus Type 1 Antibody 2G12 with Increased Neutralization Potency. Journal of Virology, 2009, 83, 98-104.	3.4	49
140	Cryo-Electron Tomography of Homophilic Adhesion Mediated by the Neural Cell Adhesion Molecule L1. Structure, 2009, 17, 460-471.	3.3	47
141	Crystal structure of TNFÎ± complexed with a poxvirus MHC-related TNF binding protein. Nature Structural and Molecular Biology, 2009, 16, 1189-1191.	8.2	28
142	Investigation of the Biophysical and Cell Biological Properties of Ferroportin, a Multipass Integral Membrane Protein Iron Exporter. Journal of Molecular Biology, 2009, 386, 717-732.	4.2	85
143	Nanogold as a Specific Marker for Electron Cryotomography. Microscopy and Microanalysis, 2009, 15, 183-188.	0.4	9
144	FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature, 2008, 455, 542-546.	27.8	150

#	Article	IF	Citations
145	Silver enhancement of Nanogold particles during freeze substitution for electron microscopy. Journal of Microscopy, 2008, 230, 263-267.	1.8	17
146	The Crystal Structure of CHIR-AB1: A Primordial Avian Classical Fc Receptor. Journal of Molecular Biology, 2008, 381, 1012-1024.	4.2	30
147	The Transferrin Receptor Modulates Hfe-Dependent Regulation of Hepcidin Expression. Cell Metabolism, 2008, 7, 205-214.	16.2	315
148	Neogenin Interacts with Hemojuvelin through Its Two Membrane-Proximal Fibronectin Type III Domains. Biochemistry, 2008, 47, 4237-4245.	2.5	52
149	The Chicken Yolk Sac IgY Receptor, a Mammalian Mannose Receptor Family Member, Transcytoses IgY across Polarized Epithelial Cells. Molecular Biology of the Cell, 2008, 19, 1587-1593.	2.1	56
150	The Human Cytomegalovirus Fc Receptor gp68 Binds the Fc C_H2-C_H3 Interface of Immunoglobulin G. Journal of Virology, 2008, 82, 3490-3499.	3.4	47
151	Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10095-10100.	7.1	80
152	Neogenin-mediated Hemojuvelin Shedding Occurs after Hemojuvelin Traffics to the Plasma Membrane. Journal of Biological Chemistry, 2008, 283, 17494-17502.	3.4	39
153	A freeze substitution fixation-based gold enlarging technique for EM studies of endocytosed Nanogold-labeled molecules. Journal of Structural Biology, 2007, 160, 103-113.	2.8	31
154	The structure of a polyQâ€“anti-polyQ complex reveals binding according to a linear lattice model. Nature Structural and Molecular Biology, 2007, 14, 381-387.	8.2	63
155	Zn-Î±2-glycoprotein, an MHC Class I-Related Glycoprotein Regulator of Adipose Tissues:â€‰ Modification or Abrogation of Ligand Binding by Site-Directed Mutagenesis. Biochemistry, 2006, 45, 2035-2041.	2.5	33
156	Crystal Structure of the HSV-1 Fc Receptor Bound to Fc Reveals a Mechanism for Antibody Bipolar Bridging. PLoS Biology, 2006, 4, e148.	5.6	75
157	Ligand Valency Affects Transcytosis, Recycling and Intracellular Trafficking Mediated by the Neonatal Fc Receptor. Traffic, 2006, 7, 1127-1142.	2.7	75
158	Finding the groove. Nature Immunology, 2006, 7, 787-789.	14.5	5
159	MHC homologs in the nervous system â€” they havenâ€™t lost their groove. Current Opinion in Neurobiology, 2006, 16, 351-357.	4.2	26
160	FcRn mediates elongated serum half-life of human IgG in cattle. International Immunology, 2006, 18, 525-536.	4.0	56
161	Structural Insights into Antibody-Mediated Mucosal Immunity. , 2006, 308, 173-204.		18
162	Composition of pH-Sensitive Triad in C-Lobe of Human Serum Transferrin. Comparison to Sequences of Ovotransferrin and Lactoferrin Provides Insight into Functional Differences in Iron Releaseâ€. Biochemistry, 2005, 44, 15451-15460.	2.5	31

#	Article	IF	Citations
163	The Molecular Mechanism for Receptor-Stimulated Iron Release from the Plasma Iron Transport Protein Transferrin. Structure, 2005, 13, 1613-1623.	3.3	46
164	Structure of a Pheromone Receptor-Associated MHC Molecule with an Open and Empty Groove. PLoS Biology, 2005, 3, e257.	5.6	43
165	Interaction of Hemojuvelin with Neogenin Results in Iron Accumulation in Human Embryonic Kidney 293 Cells. Journal of Biological Chemistry, 2005, 280, 33885-33894.	3.4	125
166	Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5981-5986.	7.1	248
167	Crystal Structure of a Secreted Insect Ferritin Reveals a Symmetrical Arrangement of Heavy and Light Chains. Journal of Molecular Biology, 2005, 349, 558-569.	4.2	86
168	pH Dependence and Stoichiometry of Binding to the Fc Region of IgG by the Herpes Simplex Virus Fc Receptor gE-gI. Journal of Biological Chemistry, 2004, 279, 14184-14193.	3.4	41
169	HFE and Transferrin Directly Compete for Transferrin Receptor in Solution and at the Cell Surface. Journal of Biological Chemistry, 2004, 279, 25866-25875.	3.4	120
170	Crystal Structure of a Polymeric Immunoglobulin Binding Fragment of the Human Polymeric Immunoglobulin Receptor. Structure, 2004, 12, 1925-1935.	3.3	97
171	Crystallographic studies of ligand binding by Zn-Î±2-glycoprotein. Journal of Structural Biology, 2004, 148, 205-213.	2.8	42
172	The Chicken Yolk Sac IgY Receptor, a Functional Equivalent of the Mammalian MHC-Related Fc Receptor, Is a Phospholipase A2 Receptor Homolog. Immunity, 2004, 20, 601-610.	14.3	126
173	Insights into IgA-mediated immune responses from the crystal structures of human FcÎ±RI and its complex with IgA1-Fc. Nature, 2003, 423, 614-620.	27.8	260
174	Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nature Immunology, 2003, 4, 913-919.	14.5	241
175	Bivalent Binding of IgA1 to FcÎ±RI Suggests a Mechanism for Cytokine Activation of IgA Phagocytosis. Journal of Molecular Biology, 2003, 327, 645-657.	4.2	113
176	Mechanism for Multiple Ligand Recognition by the Human Transferrin Receptor. PLoS Biology, 2003, 1, e51.	5.6	108
177	Heterotypic interactions between transferrin receptor and transferrin receptor 2. Blood, 2003, 101, 2008-2014.	1.4	41
178	A linear lattice model for polyglutamine in CAG-expansion diseases. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11634-11639.	7.1	129
179	Crystal structure of LIR-2 (ILT4) at 1.8 Ã…: differences from LIR-1 (ILT2) in regions implicated in the binding of the Human Cytomegalovirus class I MHC homolog UL18. BMC Structural Biology, 2002, 2, 6.	2.3	48
180	IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution. EMBO Journal, 2002, 21, 590-601.	7.8	26

#	Article	IF	Citations
181	The molecular mechanism of sulfated carbohydrate recognition by the cysteine-rich domain of mannose receptor11Edited by I. A. Wilson. Journal of Molecular Biology, 2001, 305, 481-490.	4.2	30
182	Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites. Journal of Molecular Biology, 2001, 313, 385-397.	4.2	116
183	Molecular Competition for NKG2D. Immunity, 2001, 15, 201-211.	14.3	118
184	Crystal Structure at 2.8 Ã... of an FcRn/Heterodimeric Fc Complex. Molecular Cell, 2001, 7, 867-877.	9.7	369
185	Hydrophobic Ligand Binding by Zn-Î±2-glycoprotein, a Soluble Fat-depleting Factor Related to Major Histocompatibility Complex Proteins. Journal of Biological Chemistry, 2001, 276, 35008-35013.	3.4	46
186	Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature, 2000, 403, 46-53.	27.8	326
187	Comparison of the Interactions of Transferrin Receptor and Transferrin Receptor 2 with Transferrin and the Hereditary Hemochromatosis Protein HFE. Journal of Biological Chemistry, 2000, 275, 38135-38138.	3.4	214
188	Crystal Structure of the Cysteine-Rich Domain of Mannose Receptor Complexed with a Sulfated Carbohydrate Ligand. Journal of Experimental Medicine, 2000, 191, 1105-1116.	8.5	123
189	Crystal Structure and Immunoglobulin G Binding Properties of the Human Major Histocompatibility Complex-Related Fc Receptor,. Biochemistry, 2000, 39, 9698-9708.	2.5	233
190	Crystal Structure and Ligand Binding Properties of the D1D2 Region of the Inhibitory Receptor LIR-1 (ILT2). Immunity, 2000, 13, 727-736.	14.3	125
191	Characterization of the Interaction between the Herpes Simplex Virus Type I Fc Receptor and Immunoglobulin G. Journal of Biological Chemistry, 1999, 274, 6911-6919.	3.4	44
192	Contributory presentations/posters. Journal of Biosciences, 1999, 24, 33-198.	1.1	0
193	Tolerization of adult mice to immunodominant proteins before monoclonal antibody production. Journal of Immunological Methods, 1999, 222, 59-63.	1.4	13
194	Characterization of the 2:1 Complex between the Class I MHC-Related Fc Receptor and Its Fc Ligand in Solutionâ€. Biochemistry, 1999, 38, 12639-12647.	2.5	106
195	Crystal Structure of Human ZAG, a Fat-Depleting Factor Related to MHC Molecules. Science, 1999, 283, 1914-1919.	12.6	127
196	Crystal Structure of Invasin: A Bacterial Integrin-Binding Protein. Science, 1999, 286, 291-295.	12.6	265
197	The Inhibitory Receptor LIR-1 Uses a Common Binding Interaction to Recognize Class I MHC Molecules and the Viral Homolog UL18. Immunity, 1999, 11, 603-613.	14.3	325
198	Stoichiometry of the Interaction between the Major Histocompatibility Complex-Related Fc Receptor and Its Fc Ligandâ€. Biochemistry, 1999, 38, 9471-9476.	2.5	66

#	Article	IF	Citations
199	The Transferrin Receptor Binding Site on HFE, the Class I MHC-related Protein Mutated in Hereditary Hemochromatosis. Journal of Molecular Biology, 1999, 289, 1109-1118.	4.2	84
200	The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor 1 1Edited by I. A. Wilson. Journal of Molecular Biology, 1999, 294, 239-245.	4.2	169
201	Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure, 1998, 6, 63-73.	3.3	169
202	Unusual MHC-like molecules; CD1, Fc receptor, the hemochromatosis gene product, and viral homologs. Current Opinion in Immunology, 1998, 10, 67-73.	5.5	45
203	Crystal Structure of the Hemochromatosis Protein HFE and Characterization of Its Interaction with Transferrin Receptor. Cell, 1998, 93, 111-123.	28.9	598
204	Computational determination of the structure of rat fc bound to the neonatal fc receptor 1 1Edited by I. A. Wilson. Journal of Molecular Biology, 1998, 282, 217-225.	4.2	22
205	Crystal Structure of Hemolin: A Horseshoe Shape with Implications for Homophilic Adhesion. , 1998, 281, 991-995.		157
206	Modulation of Natural Killer Cell Cytotoxicity in Human Cytomegalovirus Infection: The Role of Endogenous Class I Major Histocompatibility Complex and a Viral Class I Homolog. Journal of Experimental Medicine, 1998, 187, 1681-1687.	8.5	176
207	Characterization of a Murine Cytomegalovirus Class I Major Histocompatibility Complex (MHC) Homolog: Comparison to MHC Molecules and to the Human Cytomegalovirus MHC Homolog. Journal of Virology, 1998, 72, 460-466.	3.4	65
208	Expression and Circular Dichroism Studies of the Extracellular Domain of the Î± Subunit of the Nicotinic Acetylcholine Receptor. Journal of Biological Chemistry, 1997, 272, 25468-25473.	3.4	37
209	Identification of critical IgG binding epitopes on the neonatal Fc receptor. Journal of Molecular Biology, 1997, 274, 597-607.	4.2	85
210	MHC Restriction in Three Dimensions: A View of T Cell Receptor/Ligand Interactions. Cell, 1997, 89, 167-170.	28.9	88
211	High-Affinity Binding of the Neonatal Fc Receptor to Its IgG Ligand Requires Receptor Immobilization. Biochemistry, 1997, 36, 9374-9380.	2.5	73
212	Biochemical characterization and crystalization of human Zn-Â2-glycoprotein, a soluble class I major histocompatibility complex homolog. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 4626-4630.	7.1	53
213	Circular dichroism determination of class I MHCâ€peptide equilibrium dissociation constants. Protein Science, 1997, 6, 1771-1773.	7.6	37
214	Peptide Interaction with a Class I Major Histocompatibility Complex-Encoded Molecule:Â Allosteric Control of the Ternary Complex Stabilityâ€. Biochemistry, 1996, 35, 14841-14848.	2.5	33
215	Fc RECEPTORS AND THEIR INTERACTIONS WITH IMMUNOGLOBULINS. Annual Review of Cell and Developmental Biology, 1996, 12, 181-220.	9.4	277
216	The (Greek) Key to Structures of Neural Adhesion Molecules. Neuron, 1996, 16, 261-273.	8.1	101

#	Article	IF	Citations
217	Extended repertoire of permissible peptide ligands for HLAâ€B*2702. Protein Science, 1996, 5, 2080-2088.	7.6	18
218	BIAcore: a microchip-based system for analyzing the formation of macromolecular complexes. Structure, 1995, 3, 331-333.	3.3	37
219	The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity, 1995, 3, 583-590.	14.3	138
220	Analysis of the pH Dependence of the Neonatal Fc Receptor/Immunoglobulin G Interaction Using Antibody and Receptor Variants. Biochemistry, 1995, 34, 14649-14657.	2.5	304
221	Phosphatidyl inositol-linked forms of a murine class I MHC molecule expressed on Chinese hamster ovary cells retain peptide binding capability and alloreactivity. International Immunology, 1994, 6, 307-314.	4.0	6
222	Crystal structure at 2.2 Ã... resolution of the MHC-related neonatal Fc receptor. Nature, 1994, 372, 336-343.	27.8	311
223	Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature, 1994, 372, 379-383.	27.8	447
224	Structures of two classes of MHC molecules elucidated: crucial differences and similarities. Current Opinion in Structural Biology, 1994, 4, 852-856.	5.7	45
225	Crystal structure of tandem type III fiibronectin domains from drosophila neuroglian at 2.0 Ã¥. Neuron, 1994, 12, 717-731.	8.1	117
226	Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity, 1994, 1, 303-315.	14.3	144
227	Effects of Peptide Length and Composition on Binding to an Empty Class I MHC Heterodimer. Biochemistry, 1994, 33, 8149-8158.	2.5	58
228	Crystallization and Stoichiometry of Binding of a Complex between a Rat Intestinal Fc Receptor and Fc. Journal of Molecular Biology, 1993, 230, 1077-1083.	4.2	81
229	The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. Biochemistry, 1993, 32, 8654-8660.	2.5	100
230	Thermal stability comparison of purified empty and peptide-filled forms of a class I MHC molecule. Science, 1992, 258, 1658-1662.	12.6	138
231	Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 638-642.	7.1	98
232	Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Ã... resolution. Journal of Molecular Biology, 1991, 219, 277-319.	4.2	1,073
233	Generation of monoclonal antibodies against soluble human T cell receptor polypeptides. European Journal of Immunology, 1991, 21, 2111-2119.	2.9	27
234	Structure, Function, and Diversity of Class I Major Histocompatibility Complex Molecules. Annual Review of Biochemistry, 1990, 59, 253-288.	11.1	664

#	Article	IF	Citations
235	Structure of a Human Histocompatibility Molecule: Implications for its Interactions with Peptides and T Cell Receptors. , 1990, , 19-34.		1
236	Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature, 1989, 342, 692-696.	27.8	674
237	Model for the Interaction of T-cell Receptors with Peptide/MHC Complexes. Cold Spring Harbor Symposia on Quantitative Biology, 1989, 54, 365-373.	1.1	31
238	Data Collection from Very Thin HLA Crystals Using Synchrotron Radiation. , 1989, 51, 123-131.		0
239	A hypothetical model of the foreign antigen binding site of Class II histocompatibility molecules. Nature, 1988, 332, 845-850.	27.8	1,161
240	T-cell antigen receptor genes and T-cell recognition. Nature, 1988, 334, 395-402.	27.8	3,008
241	Structure of the human class I histocompatibility antigen, HLA-A2. Nature, 1987, 329, 506-512.	27.8	3,398
242	The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature, 1987, 329, 512-518.	27.8	2,363
243	Crystallization and X-ray diffraction studies on the histocompatibility antigens HLA-A2 and HLA-A28 from human cell membranes. Journal of Molecular Biology, 1985, 186, 205-210.	4.2	64